Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIP236 in advanced solid tumors
NCT05712889Phase 1Completed
- Sponsor
- Vincerx
- Start
- Jan 2023
- Primary completion
- Oct 2024
- Modality
- Prodrugs/Conditional Activator Small Molecules, Peptide-Drug Conjugates
- Countries
- 2
01
Overview
Phase 1, open-label trial of VIP236 in solid tumor (2 arms), sponsored by Vincerx. Primary endpoints: Incidence of Dose Limiting Toxicity and Number of participants with adverse events. Started Jan 2023; status: completed.
02
Drugs
VIP236
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05712889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05712889.